| Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast … T Tanei, K Morimoto, K Shimazu, SJ Kim, Y Tanji, T Taguchi, Y Tamaki, ... Clinical cancer research 15 (12), 4234-4241, 2009 | 718 | 2009 |
| Stem cell marker aldehyde dehydrogenase 1‐positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and … K Morimoto, SJ Kim, T Tanei, K Shimazu, Y Tanji, T Taguchi, Y Tamaki, ... Cancer science 100 (6), 1062-1068, 2009 | 322 | 2009 |
| Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer T Tanei, A Shimomura, K Shimazu, T Nakayama, SJ Kim, T Iwamoto, ... European Journal of Surgical Oncology (EJSO) 37 (2), 155-161, 2011 | 112 | 2011 |
| Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment K Yokoi, M Kojic, M Milosevic, T Tanei, M Ferrari, A Ziemys Cancer research 74 (16), 4239-4246, 2014 | 101 | 2014 |
| Emerging technologies for real‐time intraoperative margin assessment in future breast‐conserving surgery AR Pradipta, T Tanei, K Morimoto, K Shimazu, S Noguchi, K Tanaka Advanced Science 7 (9), 1901519, 2020 | 98 | 2020 |
| Correlation of methylated circulating tumor DNA with response to neoadjuvant chemotherapy in breast cancer patients H Takahashi, N Kagara, T Tanei, Y Naoi, M Shimoda, A Shimomura, ... Clinical breast cancer 17 (1), 61-69. e3, 2017 | 80 | 2017 |
| Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases T Tanei, F Leonard, X Liu, JF Alexander, Y Saito, M Ferrari, B Godin, ... Cancer research 76 (2), 429-439, 2016 | 75 | 2016 |
| Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments K Yokoi, T Tanei, B Godin, AL van de Ven, M Hanibuchi, A Matsunoki, ... Cancer Letters 345 (1), 48-55, 2014 | 70 | 2014 |
| Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells T Tanei, DS Choi, AA Rodriguez, DH Liang, L Dobrolecki, M Ghosh, ... Breast Cancer Research 18, 1-9, 2016 | 64 | 2016 |
| PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer AM Ohara, Y Naoi, K Shimazu, N Kagara, M Shimoda, T Tanei, T Miyake, ... Breast cancer research and treatment 173, 533-543, 2019 | 61 | 2019 |
| Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients Y Naoi, K Kishi, T Tanei, R Tsunashima, N Tominaga, Y Baba, SJ Kim, ... Breast cancer research and treatment 128, 633-641, 2011 | 61 | 2011 |
| Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions F Leonard, LT Curtis, P Yesantharao, T Tanei, JF Alexander, M Wu, ... Nanoscale 8 (25), 12544-12552, 2016 | 59 | 2016 |
| Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer Y Tabuchi, M Shimoda, N Kagara, Y Naoi, T Tanei, A Shimomura, ... Breast cancer research and treatment 157, 55-63, 2016 | 58 | 2016 |
| Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing C Mishima, N Kagara, T Tanei, Y Naoi, M Shimoda, A Shimomura, ... Breast cancer research and treatment 152, 305-312, 2015 | 52 | 2015 |
| Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer A Hori, M Shimoda, Y Naoi, N Kagara, T Tanei, T Miyake, K Shimazu, ... Breast Cancer Research 21, 1-18, 2019 | 48 | 2019 |
| Cascade reaction in human live tissue allows clinically applicable diagnosis of breast cancer morphology T Tanei, AR Pradipta, K Morimoto, M Fujii, M Arata, A Ito, M Yoshida, ... Advanced Science 6 (2), 1801479, 2019 | 43 | 2019 |
| Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing T Yanagawa, N Kagara, T Miyake, T Tanei, Y Naoi, M Shimoda, ... Breast cancer research and treatment 163, 231-240, 2017 | 40 | 2017 |
| Prediction of pathologic complete response to sequential paclitaxel and 5‐fluorouracil/epirubicin/cyclophosphamide therapy using a 70‐gene classifier for breast cancers Y Naoi, K Kishi, T Tanei, R Tsunashima, N Tominaga, Y Baba, SJ Kim, ... Cancer 117 (16), 3682-3690, 2011 | 38 | 2011 |
| A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells Y Chihara, M Shimoda, A Hori, A Ohara, Y Naoi, J Ikeda, N Kagara, ... Breast cancer research and treatment 166, 55-68, 2017 | 37 | 2017 |
| Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier K Yokoi, D Chan, M Kojic, M Milosevic, D Engler, R Matsunami, T Tanei, ... Journal of Controlled Release 217, 293-299, 2015 | 37 | 2015 |
